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Abstract
Background: Procalcitonin (PCT) is a marker for sepsis diagnosis, identification of bacterial infection and 
monitoring of antibiotic therapy. It has been shown that PCT is not a good choice in patients with hemodialysis. 
Therefore, we have explored two biomarkers: a) presepsin, and, b) midregion-proadrenomedullin (MR-proADM) in 
patients having End-Stage Renal Disease (ESRD). 
Patients and Methods: We prospectively enlisted 20 patients, who underwent cardiovascular surgery and had 
been on dialysis. The diagnosis of sepsis has been established clinically and confirmed by PCT. Blood samples were 
taken before and after dialysis. Additionally, plasma and sera of 10 healthy blood donors without any complications 
were used as controls. 
Results: Presepsin plasma concentrations (4368 ± 3088 vs. 694.1 ± 239.1 pg/mL) were significantly higher 
in patients with sepsis compared with controls (p<0.0001), but without significance between survivors and non-
survivors (p=0.77). Circulating levels of MR-proADM (4.15 ± 2.72 vs. 0.294 ± 0.03 nmol/L) were also elevated in 
ESRD patients (p>0.05) with no significance between alive and deceased (p=0.53) patients. Adjustments have 
shown that the difference for MR-proADM level is due to the random sampling variability (p=0.989), whereas 
difference for presepsin remained highly significant (p<0.001). 
Conclusions: Our results indicate that the accuracy of new biomarkers is equal to that of PCT in patients with 
ESRD. Presepsin might be as good marker in repeated measurements, before and after dialysis, as it is PCT.
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Introduction
According to epidemiological information the incidence of sepsis 
is increasing markedly from year to year [1,2]. Despite the efforts to 
define and recognize sepsis in early stage of the disease sepsis remains 
a serious condition. Hospital mortality due to sepsis has ranged from 
25 to 80% over the last few decades [3,4]. The cost of treating patients 
with acute myocardial infarction is lower than treating patients with 
sepsis [4]. Mortality of sepsis is a serious problem especially in surgical 
Intensive Care Units (ICUs) whose patients underwent emergent, 
urgent, or elective operations.  
Surgical interventions trigger endotoxin and cytokine release 
[5,6]. Several biomarkers have been investigated for their accuracy to 
diagnose sepsis, to provide a prognosis and to monitor successfulness 
of antimicrobial therapy. Procalcitonin (PCT) is one among them and 
it is widely used from ninety’s [7]. We have previously reported our 
experience with PCT monitoring in patients who underwent cardiac 
surgery but the efficiency of PCT is still under discussion in some 
situations [8]. There is a subgroup of patients with End-Stage Renal 
Disease (ESRD), on chronic dialysis, scheduled for elective cardiac 
surgery. Cardiovascular diseases are predominant cause of death in 
these patients. Mortality rate of the patients with ESRD after cardiac 
surgery is between 13-67% [9]. PCT is a small protein with molecular 
weight of 12.7 kDa [10]. Due to its small size it is reported to be 
eliminated during dialysis. Thereafter, PCT as a marker is under doubt 
when supervising antibiotic efficiency in patients on dialysis. 
The usefulness of presepsin as a diagnostic marker of sepsis has been 
reported [11-13]. Presepsin is a soluble subunit of the CD14 molecule, 
expressed on monocytes and other cell lines [14]. The physiological 
role of the sCD14 subunit is yet unknown but 2 mechanisms of its 
production are described: first, it is released from monocytes, and 
second, it is secreted via a signaling pathway [11,15]. However, as the 
level presepsin increases within 2-3 h after the sepsis development it is 
reasonable to conclude that presepsin is more likely to be released than 
secreted. The soluble fraction of CD14 exists in 2 forms, a 49 kDa form 
and a 55 kDa form [16].
Kitamura et al. described and specified a new protein with 
hypotensive properties from human pheochromocytoma, and named 
it Adrenomedullin (ADM) [17]. Its preprotein, a more stable mid-
regional fragment of proadrenomedullin (MR-proADM) is suitable for 
measuring in the peripheral circulation, and it was identified in plasma 
of patients with septic shock [18]. Its molecular mass is not well defined 
yet [19].
In this study we compared the usefulness of 2 new biomarkers 
against PCT: a) presepsin, i.e. soluble CD14 molecule subtype (sCD14-
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PCT concentrations in serum were measured by Time-Resolved 
Amplified Cryptate Emission (TRACE) assay with the commercially 
available PCT test (B.R.A.H.M.S Diagnostic Gmbh, Henningsdorf/
Berlin, and Germany). A PCT level of 2.0 ng/mL was considered as a 
proof of sepsis [6]. 
C-reactive protein (CRP) levels were measured by quantitative 
immuno-turbidimetric method for high sensitivity CRP (hsCRP) 
(BIOKIT, Barcelona, Spain). 
Whole blood or EDTA plasma was used for presepsin measurement 
on the PATHFAST immunoanalyzer (Mitsubishi Chemical Medience 
Corp., Tokyo, Japan) by Chemiluminiscent Enzyme Immunoassay 
(CLEIA). The recommended cut off level for sepsis was 600 pg/mL [14]. 
MR-proADM was detected in EDTA plasma using TRACE assay 
with the commercially available MR-proADM test (B.R.A.H.M.S 
Diagnostic Gmbh, Henningsdorf/Berlin, Germany). For the diagnosis 
of sepsis reference range from 0.72 to 25.4 nmol/L was recommended 
[18]. 
On the basis of serum PCT concentrations, the use of antibiotics 
was encouraged or discouraged, with cut off level of 0.5 ng/mL [20]. 
No antibiotic therapy was administrated routinely in the absence of 
clinical signs of infection or positive bacteriology.
Statistical analysis
Statistical analysis was performed by using SPSS 11.0 software 
(SPSS, Chicago, IL). Data were presented as mean ± standard deviation. 
If continuous data were not normally distributed, data were expressed 
as a median (minimum-maximum) and the Kolmogorov-Smirnov test 
was used. Intergroup differences were assessed by two-way ANOVA 
if continuous data were normally distributed and by Mann Whitney 
Rank Sum test if continuous data were not normally distributed. 
Statistical significance was accepted at p<0.05 two-tailed. 
Results
Table 1 shows the baseline characteristics of the patients. The 
operative data are shown in Table 2. Of all the patients with ESRD, 
35% underwent isolated coronary artery bypass grafting, 25% had 
replacement or reconstruction of one or more valves, 25% underwent 
combined procedures CABG and valve, and 15% had vascular surgery, 
radiofrequency ablation, or complicated cardiac interventions. 
All these patients developed sepsis during peri-operative period. 
Figure 1 shows the mean values of PCT, presepsin, MR-proADM 
and hsCRP in patients with ESRD who developed sepsis after 
cardiovascular surgery, compared with healthy controls. There was a 
significant difference for presepsin (4368 ± 3088 vs. 694.1 ± 239.1 pg/
mL; P<0.001), whereas for MR-proADM level (4.15 ± 2.72 vs. 0.294 
± 0.03 nmol/L; P=0.989) the difference was attributed to random 
sampling variability (P>0.05). The same was found for PCT (P=0.902) 
and hsCRP (P=0.902). Laboratory data are shown in Table 3. We did 
not find significant differences between survivors and non-survivors 
concerning biomarker levels: PCT (9.66 ± 17.55 vs.14.93 ± 20.54; 
p=0.42), presepsin (4184.1 ± 3039.5 vs. 4593.5 ± 3316.2; p=0.77), 
MR-proADM (3.84 ± 2.07 vs. 4.47 ± 3.5; p=0.53), hsCRP (122.4 ± 
89.3 vs. 123.07 ± 87.5; p=0.67) and BNP (819.4 ± 473.1 vs. 1860.6 ± 
1701.5; p=0.16). Table 4 has shown the overview of the distribution 
of presepsin, MR-proADM, PCT and hsCRP values in patients with 
sepsis after ESRD and cardiovascular surgery.
Figure 2 shows the mean values of presepsin and MR-proADM 
levels measured before and after dialysis in patients with sepsis, proven 
ST), and, b) MR-proADM in patients with ESRD having sepsis during 
their post-operative course. 
Patients and Methods
Patients 
This study was a prospective, observational, trial in ESRD patients 
with sepsis, on chronic dialysis, following cardiac surgery. After 
obtaining approval from the Ethics Committee and written informed 
consent from each patient, this study included 20 consecutive 
patients (5 women, 15 men; aged 33 to 73 years; mean 62.4 ± 43.4) 
scheduled to undergo open heart surgery. We assessed patients who 
were selected for elective cardiac surgery from December/2011 until 
June/2012 at the 200-bed academic tertiary care hospital having 
ESRD. The criterion for inclusion in the study was the type of the 
operation: Coronary Artery Bypass Grafting (CABG) surgery, valve 
reconstruction, combined CABG and valve procedures, thoracic aortic 
surgery, abdominal aortic aneurysm, reoperation, and radiofrequent 
ablations. Entry criteria for investigation included patients admitted 
to the ICU, who were diagnosed as having sepsis (n=20), according 
to the guidelines of the American College of Chest Physicians/Society 
of Critical Care Medicine Consensus Conference Committee [5]. Nine 
patients submitted to surgical procedure were on chronic hemodialysis 
program, whereas 11 of them developed acute renal dysfunction and 
were dialyzed for the first time after surgery. ESRD patients on dialysis 
without sepsis (according to ACCP/SCCM Consensus Conference) 
were excluded [5]. Ten healthy volunteers from the Department of 
Transfusion without any complains were included as a control group.
Thereafter, we monitored patients from admission to ICU, and 
the entire hospital stay. The clinical investigation, including body 
temperature, microbiologic examinations and chest radiograph, 
was performed daily until ICU discharge. The Sequential Organ 
Failure Assessment (SOFA) score and Acute Physiology and Chronic 
Health Evaluation (APACHE II) were routinely obtained at the first 
postoperative day, and was repeated once daily at 5:00 AM until 
discharge from ICU. Microbiologic examinations such as sputum, 
blood, and urine samples for culture were performed routinely on 
patients when infection, bacteriemia, or sepsis was suspected. Details 
on the length of ICU stay, the hospital stay, and the mortality rates were 
obtained from the hospital admission database.
Procedure for hemodialysis (HD)
All patients accepted for an elective operation underwent dialysis 
on the day before the operation, and all patients had intraoperative 
hemofiltration on Cardiopulmonary Bypass (CPB). The target value 
for perioperative hemoglobin concentration was 10 g/L or higher. 
For myocardial protection, patients received antegrade hypothermic 
(4°C) crystalloid (St. Thomas cardioplegia), and CPB performed at 
moderate systemic hypothermia (25°C to 32°C). Post-operatively, 
the dialysis was started after hemodynamic stabilization. In the case 
of acute exacerbation of chronic renal failure, in order to be stabilized 
hemodynamically, patients received continuous veno-venous 
hemodiafiltration [20]. 
Assays 
Blood samples were collected before induction of dialysis and 1 h 
after the HD session. Blood was taken from the cannulated fistula and 
immediately centrifuged for 20 min. Serum was divided into 2 aliquots 
for biochemical analysis and for measurement of inflammatory 
parameters. Leukocyte and platelet count was determined using a 
Coulter counter HmX (Coulter Electronics, Luton, England).
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by PCT. Although we have found decrease in PCT and MR-proADM 
levels following HD, there were not found statistical differences in 
plasma concentrations of all three biomarkers measured before and 
after dialysis sessions.
Type of surgery and mortality rate during the study period are 
given in Table 2. Postoperative stay at the ICU was 19.6 ± 16.4 (range, 
2 to 57) days and total hospital stay 26.5 ± 20 (range, 6 to 80) days. The 
in-hospital mortality rate was 35% (7/20); one patient passed away with 
diagnosis of cardiac arrest upon assystolia and 6 patients died due to 
institio cordis, multiorgan dysfunction and sepsis. Four patients (20%) 
died within 30 days, 4/20 (20 %) died within 6 months, and 1/20 (5%) 
died 1 year after the operation. Two patients died due to cardiac events, 
one patient 3 months and another 8 months after discharge.
Discussion
Cardiac surgery provokes an inflammatory response that 
contributes to the renal insult [21,22]. Endotoxin and circulating 
inflammatory cytokines peak 4-24 h after CPB and have been directly 
associated with acute renal injury [23,24]. Acute renal dysfunction is 
a major medical problem occurring in 5% of all patients admitted to 
the hospital and 30% of those admitted to an ICU [25]. Furthermore, 
acute renal injury remains a common, serious complication of cardiac 
surgery26. Unfortunately, typical characteristics (older age, history of 
atherosclerotic vascular disease) of those presenting for cardiac surgery 
make them generally a group at high renal risk [26].
In patients treated by haemodialysis, cardiovascular complications 
and infections are the main causes of morbidity and mortality [27]. 
Biological markers of inflammation: PCT, CRP, and interleukin (IL)-6, 
have been shown to be predictive of death in ESRD patients [28-30]. In 
patients on dialysis, PCT has been extensively studied and several studies 
have reported that PCT decreased after a hemodialysis session [30,31]. 
In contrast, CRP and IL-6 levels do not differ after dialysis compared 
with pre-haemodialysis levels. The cause of this might be due to PCT 
clearance by dialysis, because of its low molecular weight or it may be 
absorbance by the filter membrane [29,31,32]. Moreover, Nishokura et 
al. specified that the PCT clearance seems to become constant at 2.3 to 
3.4 mL/min during a 5 to 24 h haemodialysis session [32]. Akbulut et al. 
found that PCT level fell from 2.13 to 1.8 ng/mL after dialysis, whereas 
CRP levels were almost unchanged [31]. Paradoxically, the kidneys 
are exposed to exotoxins and endotoxins and are also most vulnerable 
organs for infections. Once renal injury occurs, it takes several weeks 
to resolve and inflammation is permanent or enhanced [33]. However, 
the decrease in serum PCT after a haemodialysis session reduces the 
sensitivity of PCT [28]. Therefore, we explored the usefulness of 2 new 
biomarkers in septic patients. 
The findings from Spanuth and Endo indicate that presepsin 
is a promising marker for the diagnosis and prognosis of sepsis, 
particularly in predicting 30-day mortality rate [10,11]. Presepsin is a 
molecular fragment derived from sCD14 and serves as a receptor for 
complexes of Lipopolysaccharide (LPS) and LPS binding protein (LBP) 
activating the toll-like receptor 4 on monocytes/phagocytes. Based on 
enzyme inhibitor experiments it seems that sCD14-Subtype is of 13 
kDa molecular weight but this is still debated [14]. The plasma half-life 
of presepsin was reported to be 4-5 h, and mechanisms of production 
are related to the phagocytosis and cleavage from membrane. One 
could assume that presepsin constantly appears in plasma of septic 
Demographic factor Total (n = 20)
     Male sex, n (%) 15 (75)
     Age (years) 62.4 ± 43.4
     LV function (%) 37.8 ± 26.0
     Systolic blood pressure (mm/Hg) 138.3 ± 43.2
     Diastolic blood pressure (mm/Hg) 88.1 ± 61.5
     Heart rate (bpm) 80 ± 56
    NYHA classification, n (%)
          II 5 (25)
          III 10 (50)
          IV 5 (25)
Operations
     Elective, n (%) 10 (50)
     Urgent, n (%) 10 (50)
Cardiac risk factors
     Arterial hypertension, n (%) 20 (100)
     Diabetes mellitus, n (%) 8 (40)
     Hyperlipoproteinemia, n (%) 14 (70)
     Previous cardiovascular diseases, n (%) 20 (100)
     History of smoking, n (%)  8 (40)
     Obesity, n (%) 10 (50)
     Family history, n (%)  9 (45)
Preoperative events
     Myocardial infarction, n (%) 9 (45)
     Repeat myocardial infarction, n (%) 2 (10)
     Myocardial infarction after PCI x2, n (%) 1 (5)
     Cerebrovascular insult, n (%) 2 (10)
     Pulmonary oedema, n (%) 1 (5)
     Angina pectoris, n (%) 4 (20)
     Coronary revascularization, n (%) 1 (5)
     Valve replacement, n (%) 1 (5)
     Atrial fibrillation, n (%) 1 (5)
     Thoracoabdominalis aortic aneurysm, n (%) 4 (20)
End-Stage Renal Disease
     Chronic program of dialysis, n (%) 9 (45)
           Duration of dialysis (months) 46 ± 31.8
     Acute renal insufficiency, n (%) 11 (55)
Table 1: Preoperative Status of Patients with End-Stage Renal Disease. Data 
are mean ± standard deviation for continuous variables or n (%) for categorical 
variables. LV: Left Ventricle; NYHA: New York Heart Association: PCI: 
Percutaneous Coronary Intervention.
Procedure No. of Patients
No. of  
Deaths 
30 Days
No. of   
Deaths   
6 Months
No. of  
Deaths    
1 Year
Isolated CABG (x2) 2 1
Isolated CABG (x3) 4 1 1
Isolated CABG (x4) 1
AVR and MVR 1
AVR and MVR and Tricuspid valve 
reconstruction 2 1
MVR and Tricuspid valve 
reconstruction 2
Redo MVR and Tricuspid valve 
reconstruction 1 1
Bentall and CABG (x1) 1 1
Bentall and Redo CABG (x1) 1 1




Total 20 4 4 1
Table 2: Operative Procedures and Perioperative Mortality. CABG: Coronary Artery 
Bypass Grafting; AVR: Aortic Valve Replacement; MVR: Mitral Valve Replacement; 
AAA: Abdominal Aortic Aneurysm; RF: Radiofrequent; Redo: Reoperation.
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patients even during dialysis process. Although the kinetics of the 
soluble forms of the CD14 molecule, as well as sCD14-ST subunit, is 
under observation, in our study we compared the levels before and 
after dialysis. We have found that presepsin appeared to be a reliable 
diagnostic marker for identifying sepsis and that it is a more accurate 
marker to monitor antibiotics treatment in patients with ESRD, than 
PCT. 
MR-proADM is a stable peptide produced in stoichiometric 
amounts to ADM, representing the true level of the ADM in plasma 
[18,34]. ADM and related peptides are synthesized and secreted from 
vascular smooth muscle and endothelial cells. The half-life of ADM 
is 22 ± 1.6 minutes and it has potent and long-lasting vasodilatory 
effects on several vascular systems, but also metabolic and bactericidal 
properties [17,35]. Hirata et al. reported that the plasma concentrations 
of ADM increased in patients with sepsis complicated with acute renal 
disease, which declined following improvement of renal function [36]. 
The plasma ADM concentration has been shown to be increasing in 
correlation with serum creatinine in patients with chronic renal failure. 
Eto has shown that ADM decreases cardiac preload and afterload and 
improves cardiac contractility and diuresis in patients with heart failure 
and hypertension [37]. All our patients were in NYHA III or IV class 
with hypertension lasting for years. In our study, probably the MR-
proADM concentrations measured reflect compensatory mechanisms 
due to heart failure, or renal failure, but the further confirmation of the 
present findings should be done. 
Since many hormones or small fragments of peptides are known to 
be metabolized in the kidneys, the possibility of a decreased clearance 
of ADM in renal failure patients cannot be excluded as an explanation 
for the elevated plasma level. Washimine et al. reported a marked 
increase in the plasma ADM level in patients with ESRD who had 
been receiving maintenance haemodialysis [38]. In their comparison 
between plasma concentrations before and after the hemodialysis, they 
found that the increased plasma ADM was slightly reduced by dialysis, 
but the difference was not significant despite the reduction of the fluid 
volume. In our study we have found a similar trend of a drop of the 
MR-proADM levels measured after dialysis. It is in agreement with the 
findings of others who reported that plasma levels of ADM were not 
altered immediately by hemodialysis but decreased significantly 14-
20 h after dialysis [39-41]. Montuenga et al. found that ADM has a 
molecular weight of 22 kDa and it has to be considered that that the 
organs producing high levels of ADM could also be included in the 
clearance of the peptide, especially if it is not a smaller molecule than 
the diameter of the dialyzer’s aperture [19]. 
Limitation of our study is that other important markers such are 
IL-6, B-type natriuretic peptide and A-type natriuretic peptide, were 
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Mann-Whitney Rank Sum Test A) P=0.902, B) P<0.0001, C) P=0.989, and D) P=0.902.
ESRD: End-stage renal disease; hsCRP: High sensitivity C-reactive protein; MR-proADM: Mid region proadrenomedullin; PCT: Procalcitonin.
Figure 1: Concentrations of (A) PCT, (B) Presepsin, (C) MR-proADM, and (D) hsCRP in ESRD Patients with Sepsis after Cardiovascular Surgery vs. control group.
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genetic association in patients having acute renal injury after heart 
surgery. B- and A-type natriuretic peptide, both of whom have been 
associated with greater rises of proadrenomedullin levels, should be 
tested in those patients also. The main limitation is the small number 
of patients, but there are very limited studies concerning ESRD, cardiac 
surgery and sepsis. We believe that similar investigations are needed to 
attract attention to this issue. Septic patients are highly heterogeneous 
population and further scientific work is of broader interest for 
clinicians and scientific workers.
In conclusion, our results indicate that the diagnostic accuracy 
of new biomarkers is equal to that of PCT in patients with ESRD. 
Presepsin might be as good marker in repeated measurements, before 
Hematology Total (n = 20)
     WBC (10x9/L) 14.9 [6.1-28.8]
     Hemoglobin (g/L) 92.7 [77-115]
     Platelets (10x9/L) 172 [85-215]
Biochemistry   
    Sodium (mmol/L) 138.6 [132 -152]
    Serum creatinine (μmol/L) 438.7 [104 - 989]
    Serum urea (mmol/L) 20 [6.6 – 50.4]
Biomarker level
     PCT (ng/mL) 3.86 [0.4 – 58.8]
     Presepsin (pg/mL) 3145 [1374 – 11237]
     MR-proADM (nmol/L) 3.76 [0.5 – 11.12]
     CRP  (mg/L) 104.4 [8.02 – 271.0]
     BNP (ng/L) 1767 [58 – 4752]
Clinical scoring systems
     APACHE II 19 [14 – 35]
     SOFA 14 [4 – 21]
Table 3: Laboratory data on the day of sepsis appearance taken before dialysis. 
Data are expressed as median (minimum-maximum). APACHE II: Acute Physiology 
And Chronic Health Evaluation II; BNP: B-Type Natriuretic Peptide; Hscrp: High 
Sensitivity C-Reactive Protein; MR-Proadm: Mid-Region Proadrenomedullin; PCT: 
Procalcitonin; SOFA: Sequential Organ Failure Assessment; WBC: White Blood 
Cells.











Skewness coefficient 1.355 0.735 1.809 0.574
Kurtosis 0.636 0.577 2.020 -0.994
Table 4: Overview of the Distribution of Presepsin, MR-proADM, PCT and hsCRP 
Values in Patients with Sepsis after ESRD and Cardiovascular Surgery. ESRD: 
End-Stage Renal Disease; Hscrp: High Sensitivity C-Reactive Protein; MR-
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HD: Hemodialysis; MR-proADM: Mid-region proadrenomedullin; n.s: No significant differences.
Figure 2: Plasma concentrations of presepsin (A) MR-proADM (B) and procalcitonin (C) in patients with end-stage renal disease before and after hemodialysis (HD) 
following cardiovascular surgery.
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and after dialysis, as it is PCT. Preliminary results have shown that the 
measurement of presepsin is useful for monitoring antibiotic therapy 
of sepsis in patients with ESRD.
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